Compare TSSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSSI | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.1M | 204.2M |
| IPO Year | N/A | 2023 |
| Metric | TSSI | SGMT |
|---|---|---|
| Price | $11.17 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | ★ 1.4M | 504.2K |
| Earning Date | 11-13-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $234,837,000.00 | N/A |
| Revenue This Year | $54.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $60.59 | ★ N/A |
| Revenue Growth | ★ 91.66 | N/A |
| 52 Week Low | $5.63 | $1.73 |
| 52 Week High | $31.94 | $11.41 |
| Indicator | TSSI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 53.90 |
| Support Level | $10.03 | $5.95 |
| Resistance Level | $12.71 | $6.42 |
| Average True Range (ATR) | 0.98 | 0.31 |
| MACD | 0.44 | 0.09 |
| Stochastic Oscillator | 71.21 | 77.04 |
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.